9月21日 - ** Cue Biopharma(CUE.O)股价在盘前交易中飙升28.9%,至47.74美元
** 该公司宣布CUE-221用于治疗荨麻疹的中期研究取得积极结果
** 称该试验达到了II期主要终点及关键次要终点
** CUE第二季度营收在本月早些时候翻了一番多 (link)
** 截至前一交易日收盘,今年以来股价累计上涨逾300%
9月21日 - ** Cue Biopharma(CUE.O)股价在盘前交易中飙升28.9%,至47.74美元
** 该公司宣布CUE-221用于治疗荨麻疹的中期研究取得积极结果
** 称该试验达到了II期主要终点及关键次要终点
** CUE第二季度营收在本月早些时候翻了一番多 (link)
** 截至前一交易日收盘,今年以来股价累计上涨逾300%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.